New ways to treat hepatitis B and prevent primary liver cancer
Today, 25 November, 1.00-2.00pm
Join Prof Joe Trapani, Dr Mohamed Fareh and Dr Laura McCullough as they share ground-breaking liver cancer research emerging from the VCCC Alliance Centre for Cancer Immunotherapy.
In this webinar, discover how CRISPR-Cas 13 technology is disrupting the hepatitis B virus (HBV), potentially reducing the impact of chronic HBV infection and the incidence of hepatocellular cancer.
